DiaceuticsFRA:7DC +0.61%91 PEG Ratio is 24.37 as of Jul. 03, 2026, which is 114% above its 10-year median of 11.40. GuruFocus rates FRA:7DC with a GF Score™ of 91/100 and a GF Value™ of €2.14 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 225 Healthcare Providers & Services companies, Diaceutics ranks worse than 90.22% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Diaceutics's PE Ratio without NRI is 1,650.00. Diaceutics's 5-Year EBITDA growth rate is 67.70%. Therefore, Diaceutics's PEG Ratio for today is 24.37.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Diaceutics's PEG Ratio or its related term are showing as below:
FRA:7DC'
s PEG Ratio Range Over the Past 10 Years
Min: 8.45 Med: 11.4 Max: 26.09
Current: 10.98
During the past 10 years, Diaceutics's highest PEG Ratio was 26.09. The lowest was 8.45. And the median was 11.40.
FRA:7DC's PEG Ratio is ranked worse than 90.22% of 225
companies
in the Healthcare Providers & Services industry
Industry Median: 1.41
vs FRA:7DC: 10.98
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Diaceutics (FRA:7DC) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Diaceutics PEG Ratio Related Terms
Diaceutics PEG Ratio Historical Data
* Premium members only.
The historical data trend for Diaceutics's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diaceutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics PEG Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Diaceutics's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Diaceutics (FRA:7DC) has a PEG Ratio of 24.37 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Diaceutics and its competitors. This is 114% above median its historical median of 11.40. Over the past decade, Diaceutics' PEG Ratio has ranged from 8.45 to 26.09. According to the industry distribution chart, Diaceutics ranks #203 out of 225 companies in the Healthcare Providers & Services industry, placing it in the top 90.2%.
Is Diaceutics' PEG Ratio too high?
Diaceutics' current PEG Ratio of 24.37 is 114% above median its 10-year median of 11.40. Over the past 10 years, this metric has ranged from a low of 8.45 to a high of 26.09. The Healthcare Providers & Services industry median PEG Ratio is 1.41. Diaceutics' value of 24.37 is 1628.4% above this industry median. Based on the distribution chart, Diaceutics ranks #203 out of 225 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diaceutics has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' PEG Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #203 out of 225 companies for PEG Ratio. This places Diaceutics in the lower half of its industry. The industry median PEG Ratio is 1.41. Diaceutics' value of 24.37 is 1628.4% above this benchmark. Historically, Diaceutics' own PEG Ratio has ranged from 8.45 to 26.09 over the past decade. While the company's 10-year median is 11.40 vs. the industry median of 1.41, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Healthcare Providers & Services company?
The median PEG Ratio among Healthcare Providers & Services companies is 1.41, based on 225 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current PEG Ratio of 24.37 is 1628.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median PEG Ratio is 1.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current PEG Ratio is 24.37, which is 114% above median its own 10-year median of 11.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.14, compared to a current price of €1.65 — trading 22.9% below its estimated fair value. The current PEG Ratio is 24.37, which is 114% above median its 10-year median of 11.40 and 1628.4% above the Healthcare Providers & Services industry median of 1.41. Diaceutics' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current PEG Ratio is 24.37 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (FRA:7DC) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of €1.65 is trading 22.9% below its estimated GF Value™ of €2.14.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for FRA:7DC:
PEG Ratio: 24.37 (114% above median its 10-year median of 11.40)
GF Value™: €2.14 vs. price of €1.65 (22.9% below fair value)
Industry Position: 1628.4% above the Healthcare Providers & Services median (#203 of 225)
No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
91GF Score
Get the complete analysis for FRA:7DC
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7DC has been successfully added to your 
